PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Heger, L.M.* ; Kertess, L.* ; Kaufhold, C.* ; Gubinelli, F.* ; Cardona-Alberich, A.* ; Özata, G.* ; Müller, S.A.* ; Tschirner, S.K.* ; Stehling, O.* ; Schifferer, M.* ; Peron, C.* ; Tiranti, V.* ; Lill, R.* ; Iuso, A. ; Zecca, L.* ; Strupp, M.* ; Oertel, W.H. ; Lichtenthaler, S.F.* ; Burbulla, L.F.*

Patient-derived neurons exhibit α-synuclein pathology and previously unrecognized major histocompatibility complex class I elevation in mitochondrial membrane protein-associated neurodegeneration.

Mov. Disord., DOI: 10.1002/mds.70029 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Mitochondrial membrane protein-associated neurodegeneration (MPAN) from the neurodegeneration with brain iron accumulation (NBIA) family is a rare neurodegenerative disease marked by α-synuclein aggregation, brain iron accumulation, and midbrain dopaminergic neuron degeneration. OBJECTIVE: The mechanisms driving neuron vulnerability remain unclear. Our study aimed to develop a patient-derived disease model replicating key pathologies of patient brains. METHODS: We generated induced pluripotent stem cell-derived midbrain dopaminergic neurons from MPAN patients and examined ultrastructural and biochemical markers of pathology. RESULTS: MPAN patient neurons displayed α-synuclein aggregation, axonal swellings, iron accumulation, and severe membrane destruction. In addition, levels of the major histocompatibility complex class I (MHC-I), linked to cellular stress and neurodegenerative processes, were elevated in patient neurons. Treatment with acetyl-leucine, a potentially neuroprotective compound, decreased MHC-I. CONCLUSIONS: This first patient-derived neuronal model of MPAN provides a useful tool for further research aimed at unraveling the complexities of this disease and developing potential therapeutic interventions. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Impact Factor
Scopus SNIP
Altmetric
7.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Mpan ; Nbia ; Dopaminergic Neurons ; Ipsc Disease Modeling ; α‐synuclein; Parkinsons-disease; Substantia-nigra; Iron; Aggregation; Oxidation; C19orf12; Subtype
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0885-3185
e-ISSN 1531-8257
Zeitschrift Movement Disorders
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Neurogenomics (ING)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-503200-001
Förderungen NBIA Suisse
NBIA Disorders Association (NBIADA, USA), Associazione Italiana Sindromi Neurodegenerative da Accumulo di Ferro (AISNAF, Italy), Hoffnungsbaum e.V. (HoBa, Germany), and Stichting Ijzersterk (The Netherlands)
Mariani Foundation
Pezzoli Foundation for Parkinson's Disease
Linea Azione 4.1; T4-AN-09 of the Italian Ministry of health, project POS
DOI 10.1002/mds.70029
WOS ID 001570888500001
Scopus ID 105016258135
PubMed ID 40948186
Erfassungsdatum 2025-11-04
[➜Korrektur melden]